BRAF V600EPhase 3 RCTNEJM 2019來源:人工整理

EC ± binimetinib vs cetux+chemo

關鍵結果mOS 9.0 vs 5.4 mo, HR 0.52

首次證實 BRAF+EGFR 雙阻斷在 2L+ BRAF V600E mCRC 的 OS 獲益

詳細證據整理

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

Authors: Kopetz S, Grothey A, Yaeger R, et al.
Journal: N Engl J Med 2019;381:1632-1643
DOI: 10.1056/NEJMoa1908075
PMID: 31566309
Study: BEACON CRC (Phase 3)
Note: Full text for this article is not available in PubMed Central (PMC). Full text is available at https://doi.org/10.1056/NEJMoa1908075.

Abstract

Design: Phase 3 randomized trial enrolling 665 patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had progressed after 1-2 prior regimens in the metastatic setting.

Arms: Patients were randomized 1:1:1 to:

  • Triplet: encorafenib + binimetinib + cetuximab
  • Doublet: encorafenib + cetuximab
  • Control: cetuximab + irinotecan or FOLFIRI

Key Results (Interim Analysis)

Endpoint Triplet Doublet Control
Median OS 9.0 months 8.4 months 5.4 months
OS HR vs Control 0.52 (P<0.001) 0.60 --
ORR 26% -- 2%
ORR P-value P<0.001 (Triplet vs Control)
Grade ≥3 AEs 58% 50% 61%

Conclusions

The triplet combination of encorafenib, binimetinib, and cetuximab, as well as the doublet of encorafenib plus cetuximab, resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with BRAF V600E-mutant mCRC. This was the first demonstration of survival benefit for a chemotherapy-free targeted regimen in biomarker-selected patients with mCRC.

本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。

讀者討論

讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。

載入留言中…

  • GuidelineJNCCN 2026來源:摘要

    NCCN Colon Cancer v3.2026(Guidelines Insights)

    BRAF V600E 晚期治療推薦更新, 晚期治療章節依 biomarker 重組; 新增 fluoropyrimidine 前 DPYD 檢測; 依近期試驗更新非轉移性輔助治療

    NCCN 結腸癌 v3.2026 依 biomarker 重組晚期治療章節,並特別更新 BRAF V600E 推薦,承接 BREAKWATER 證據;另新增化療前 DPYD 檢測建議。Insights 摘要未列推薦等級,細節需對照指引全文

  • Phase 3 (Cohort 3)ASCO GI 2026來源:人工整理

    EC+FOLFIRI vs FOLFIRI±bev (1L)

    ORR 64.4% vs 39.2%, OR 2.76; 肝 mets ORR 79.1%

    FOLFIRI 也行——提供第二個化療骨幹選擇,特別適合 oxaliplatin 禁忌

  • Biomarker (exploratory)ESMO 2025來源:人工整理

    EC+mFOLFOX6 vs EC vs SOC

    C2D15 D/ND: 67.1% vs 45.2% vs 37.5%; resistance 6.6% vs 37.9%

    化療骨幹壓制抗藥性克隆——EC+chemo 優於 EC alone 的分子機制

  • Phase 3 RCTNat Med 2025來源:人工整理

    EC+mFOLFOX6 vs SOC (1L)

    ORR 60.9% vs 40.0%, OR 2.44

    BREAKWATER 首報:一線 EC+化療 ORR 達 61%,FDA 加速核准

看 BRAF V600E 的全部文獻